Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWOK1D)

• Drug Name: Thiomorpholine derivative 2 Drug Info
• Synonyms: PMID25482888-Compound-20
• Cross-matching ID: TTD Drug ID: DMWOK1D

Molecule-Related Drug Atlas

Drug(s) Targeting Dipeptidyl peptidase 8 (DPP-8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Talabostat	DM1IZ5D	Constitutional neutropenia	4B00.0	Phase 3	[2]
BXCL701	DMBPUIK	Prostate cancer	2C82.0	Phase 1/2	[3]
Thiomorpholine derivative 1	DMZP6KR	N. A.	N. A.	Patented	[1]
PMID20684603C24dd	DMWZK9U	Discovery agent	N.A.	Investigative	[4]
1G244	DMEB8CG	Discovery agent	N.A.	Investigative	[5]
PMID15664838C18	DM93RKC	Discovery agent	N.A.	Investigative	[6]

Drug(s) Targeting Dipeptidyl peptidase 4 (DPP-4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Saxagliptin	DMGXENV	Type-2 diabetes	5A11	Approved	[7]
Sitagliptin	DMGDKXN	Cystic fibrosis	CA25	Approved	[8]
Alogliptin	DM8WI3R	Type-2 diabetes	5A11	Approved	[9]
Linagliptin	DMWFJTR	Non-insulin dependent diabetes	5A11	Approved	[10]
Vildagliptin	DMYN59P	Type-2 diabetes	5A11	Approved	[11]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride	DM34TXO	Type-2 diabetes	5A11	Approved	[12]
Anagliptin	DMJXIC9	Type-2 diabetes	5A11	Approved	[13]
SaxaDapa FDC	DMAPRWV	Diabetic complication	5A2Y	Phase 3	[14]
LC-150444	DM09RKB	Type-2 diabetes	5A11	Phase 3	[15]
Dutogliptin	DMM5VTA	Type-2 diabetes	5A11	Phase 3	[16]

Drug(s) Targeting Dipeptidyl peptidase 9 (DPP-9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Talabostat	DM1IZ5D	Constitutional neutropenia	4B00.0	Phase 3	[2]
BXCL701	DMBPUIK	Prostate cancer	2C82.0	Phase 1/2	[3]
Thiomorpholine derivative 1	DMZP6KR	N. A.	N. A.	Patented	[1]
PMID20684603C24dd	DMWZK9U	Discovery agent	N.A.	Investigative	[4]
1G244	DMEB8CG	Discovery agent	N.A.	Investigative	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dipeptidyl peptidase 4 (DPP-4)	TTDIGC1	DPP4_HUMAN	Inhibitor	[1]
Dipeptidyl peptidase 8 (DPP-8)	TTJGLZF	DPP8_HUMAN	Inhibitor	[1]
Dipeptidyl peptidase 9 (DPP-9)	TTNDUL7	DPP9_HUMAN	Inhibitor	[1]

References

• [1] DPP-4 inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):209-36.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. J Immunother Cancer. 2021 Nov;9(11):e002837.
• [4] Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors. J Med Chem. 2010 Aug 12;53(15):5620-8.
• [5] Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8/9 inhibitor. Biochem Pharmacol. 2009 Jul 15;78(2):203-10.
• [6] Novel isoindoline compounds for potent and selective inhibition of prolyl dipeptidase DPP8. Bioorg Med Chem Lett. 2005 Feb 1;15(3):687-91.
• [7] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [8] Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
• [9] Clinical pipeline report, company report or official report of Takeda (2009).
• [10] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [11] Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [13] Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
• [14] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
• [15] Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
• [16] Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.